In conclusion, we demonstrated that use of the telomerase-targeted oncolytic adenoviruses OBP-301 and OBP-702 represents a promising therapeutic approach for the treatment of MYCN-amplified NB tumors via MYCN suppression. Here, MYCN is linked to neuroblastoma.